You have 9 free searches left this month | to do more

copanlisib

Copanlisib is a drug used to treat Anatomic Stage IV Breast Cancer AJCC v8, Follicular Lymphoma, Metastatic Breast Carcinoma, and other conditions. Copanlisib is being actively studied in 30 studies and prior, has been studied in 2.

Top SponsorsTop SitesTop Investigators
National Cancer Institute (NCI)M D Anderson Cancer CenterJennifer Crombie
M.D. Anderson Cancer CenterDana-Farber Cancer InstituteBenedito A Carneiro, MD
Memorial Sloan Kettering Cancer CenterMemorial Sloan Kettering Cancer CenterChristian Buske
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED
Z
Lung Cancer With Copanlisib and Durvalumab
Recruiting
  • Non Small Cell Lung Cancer
  • Lexington, Kentucky
    Markey Cancer Center
2022-02-21
Feb 21, 2022
N
Response-Adapted Therapy With Copanlisib and Rituximab in Untreated Follicular Lymphoma
Recruiting
  • Follicular Lymphoma
  • +2 more
  • Rituximab
  • Copanlisib
  • Bethesda, Maryland
    National Institutes of Health Clinical Center
2022-04-07
Apr 7, 2022
D
Copanlisib Plus Ibrutinib in R/R CLL
Recruiting
  • Chronic Lymphocytic Leukemia (CLL)
  • +2 more
  • Boston, Massachusetts
    Dana-Farber Cancer Institute
2021-09-08
Sep 8, 2021
D
Copanlisib Plus Venetoclax in R/R DLBCL
Recruiting
  • Diffuse Large B Cell Lymphoma
  • +2 more
  • Boston, Massachusetts
    Dana-Farber Cancer Institute
2021-09-08
Sep 8, 2021
M
Phase 2 Study of PI3K Inhibitor Copanlisib in Combination With Fulvestrant in Selected ER+ and/or PR+ Cancers With PI3K (PIK3CA, PIK3R1) and/or PTEN Alterations
Not yet recruiting
  • Endometrial Cancer
  • Ovarian Cancer
  • Houston, Texas
    M D Anderson Cancer Center
2022-03-31
Mar 31, 2022
D
Window Trial to Evaluate Molecular Response to PI3K Inhibition With Copanlisib in r/r Adult B-cell ALL
Recruiting
  • Leukemia, Acute Lymphocytic
  • Copanlisib
  • Durham, North Carolina
    Duke Cancer Center
2021-07-19
Jul 19, 2021
H
Copanlisib (BAY 80-6946) in Combination With Gemcitabine and Cisplatin in Advanced Cholangiocarcinoma - 2021
Completed
Has Results
  • Biliary Carcinoma
  • +3 more
  • Tampa, Florida
    H. Lee Moffitt Cancer Center and Research Institute
2021-08-03
Aug 3, 2021
S
Copanlisib in Combination With Venetoclax in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma. - 2022
Terminated
  • Non-Hodgkin Lymphoma
  • Basel, Switzerland
  • +5 more
2022-03-18
Mar 18, 2022
C
Phase Ib/II Trial of coPANlisib in Combination With Trastuzumab in HER2-positive Breast Cancer. (Panther Study)
Active, not recruiting
  • HER2 Positive Breast Cancer
  • Cork, Ireland
  • +4 more
2021-10-08
Oct 8, 2021
M
BAY1895344 and Copanlisib for the Treatment of Molecularly Selected Patients With Advanced Solid Tumors
Not yet recruiting
  • Locally Advanced Malignant Solid Neoplasm
  • +3 more
  • Houston, Texas
    M D Anderson Cancer Center
2021-08-10
Aug 10, 2021
C
Study of Copanlisib and Ketogenic Diet
Recruiting
  • Follicular Lymphoma
  • Endometrial Cancer
  • Copanlisib
  • Ketogenic Diet
  • New York, New York
  • +2 more
2021-11-24
Nov 24, 2021
B
A Study of Copanlisib Combined With Rucaparib in Patients With Metastatic Castration-resistant Prostate Cancer
Recruiting
  • Metastatic Castration-resistant Prostate Cancer
  • San Francisco, California
  • +1 more
2021-11-18
Nov 18, 2021
N
Copanlisib With Dose-Adjusted EPOCH-R in Relapsed and Refractory Burkitt Lymphoma and Other High-Grade B-cell Lymphomas
Recruiting
  • Burkitt Lymphoma
  • +4 more
  • Rituximab
  • +6 more
  • Bethesda, Maryland
    National Institutes of Health Clinical Center
2022-04-07
Apr 7, 2022
C
Copanlisib and Nivolumab in Treating Patients With Richter's Transformation or Transformed Indolent Non-Hodgkin Lymphoma
Recruiting
  • Chronic Lymphocytic Leukemia
  • +6 more
  • Copanlisib
  • Nivolumab
  • Duarte, California
  • +2 more
2022-03-09
Mar 9, 2022
B
An Study to Evaluate the Safety and Efficacy of Copanlisib in Combination With Nivolumab in Patients With Advanced Solid Tumors
Active, not recruiting
  • Non-small Cell Lung Cancer (NSCLC)
  • +2 more
  • Beverly Hills, California
  • +5 more
2022-03-28
Mar 28, 2022
U
Copanlisib in Combination With Rituximab and CHOP Chemotherapy in Patients With Previously Untreated DLBCL
Recruiting
  • Diffuse Large B Cell Lymphoma
  • Copanlisib
  • R-CHOP Chemotherapy
  • Aachen, Germany
  • +9 more
2021-10-19
Oct 19, 2021
B
Dose De-escalation Study of the PI3k Alpha/Delta Inhibitor, Copanlisib Given in Combination With the Immunotherapeutic Agents, Nivolumab and Rituximab in Patients With Relapsed/Refractory Indolent Lymphoma
Recruiting
  • Indolent Lymphoma
  • Copanlisib
  • +2 more
  • Chicago, Illinois
  • +3 more
2021-10-26
Oct 26, 2021
U
Bendamustine and Rituximab in Combination With Copanlisib for the Treatment of Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma - 2021
Terminated
  • Lymphoid Leukemia
  • +3 more
  • Copanlisib
  • +2 more
  • Seattle, Washington
    Fred Hutch/University of Washington Cancer Consortium
2021-07-20
Jul 20, 2021
M
Copanlisib With Ibrutinib for Patients With Recurrent/ Refractory Primary Central Nervous System Lymphoma (PCNSL)
Recruiting
  • Refractory/Recurrent Primary Central Nervous System Lymphoma (PCNSL)
  • Basking Ridge, New Jersey
  • +6 more
2022-03-28
Mar 28, 2022
M
A Study of Copanlisib and Ibrutinib in Mantle Cell Lymphoma
Active, not recruiting
  • Mantle Cell Lymphoma (MCL)
  • Basking Ridge, New Jersey
  • +5 more
2021-04-14
Apr 14, 2021
N
A Study of a New Drug Combination, Copanlisib and Fulvestrant, in Advanced Breast Cancer
Recruiting
  • Anatomic Stage IV Breast Cancer AJCC v8
  • +3 more
  • Sacramento, California
  • +7 more
2022-03-25
Mar 25, 2022
C
Copanlisib in Combination With T-DM1 in Pretreated Unresectable Locally Advanced or Metastatic HER2-positive Breast Cancer - 2020
Terminated
  • HER2-positive Breast Cancer
  • +3 more
  • Copanlisib
  • Trastuzumab emtansine
  • Cork, Ireland
  • +3 more
2020-12-14
Dec 14, 2020
J
Copanlisib, Letrozole, and Palbociclib in Treating Patients With Hormone Receptor Positive HER2 Negative Stage I-IV Breast Cancer
Active, not recruiting
  • Estrogen Receptor Positive
  • +16 more
  • Biopsy of Breast
  • +5 more
  • Los Angeles, California
    UCLA / Jonsson Comprehensive Cancer Center
2021-10-07
Oct 7, 2021
M
Vemurafenib Plus Copanlisib in Radioiodine-Refractory (RAIR) Thyroid Cancers
Recruiting
  • Thyroid Carcinoma
  • +5 more
  • I-124 PET/CT lesion dosimetry
  • +2 more
  • Basking Ridge, New Jersey
  • +6 more
2022-03-03
Mar 3, 2022
C
Copanlisib in Combination With Romidepsin in Patients With Relapsed or Refractory Mature T-cell Lymphoma
Withdrawn
  • Lymphoma, T-Cell
  • (no location specified)
2020-08-11
Aug 11, 2020